在充满挑战的时代,药物发现的弹性途径
Sean Ekins1, Barbara S Slusher2
1Collaborations Pharmaceuticals, Inc., Raleigh, NC 27606, USA.
Trends in pharmacological sciences
|November 27, 2025
概括
拟议的国家卫生研究院 (NIH) 预算削减威胁到美国的药物发现. 像人工智能 (AI),多样化的资金和全球合作等策略可以确保科学进步,尽管存在挑战.
科学领域:
- 生物医学研究的研究.
- 药物的发现和开发.
- 卫生政策 卫生政策
背景情况:
- 美国国家卫生研究院 (NIH) 面临预算削减的建议.
- 学术和小型生物制药药物发现领域面临重大风险.
- 当前政府的财政政策影响了科学研究的资金.
研究的目的:
- 确定可行的策略,以保持药物发现的科学进步.
- 为应对潜在的NIH预算削减所带来的挑战.
- 为学术和小型生物制药公司提供解决方案.
主要方法:
- 审查当前的融资格局和政策影响.
- 对新兴技术和协作模式的分析.
- 评估商业化和公众参与策略.
主要成果:
- 人工智能 (AI) 为加速药物发现提供了强大的工具.
- 除了联邦拨款之外,多元化资金来源至关重要.
- 加强商业化,许可和全球合作伙伴关系可以减轻风险.
- 加强公众参与对于持续的科学支持至关重要.
结论:
- 尽管拟议的NIH预算削减,但在药物发现领域的科学进展是可以实现的.
- 必须采用多方面的方法,包括技术,多样化的资金和合作.
- 积极的战略对于美国药物发现生态系统的弹性是必要的.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.5K
05:10Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
10.1K
相关概念视频
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Factors Affecting Drug Response: Overview
2.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.8K
Drug Clearance: Overview
361
Drug elimination refers to drug removal from the body, either through urine or bile, by the kidneys or liver, respectively. A pharmacokinetic parameter, drug clearance, measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the drug's concentration in plasma.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
361
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
